Reuters logo
BRIEF-Genmab: Darzalex approved for relapsed or refractory multiple myeloma in Japan
September 27, 2017 / 5:52 AM / in 3 months

BRIEF-Genmab: Darzalex approved for relapsed or refractory multiple myeloma in Japan

Sept 27 (Reuters) - GENMAB A/S

* ANNOUNCES APPROVAL OF DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN JAPAN

* ‍TO RECEIVE USD 25 MILLION IN MILESTONE PAYMENTS UPON FIRST COMMERCIAL SALE IN JAPAN​

* ‍IF FIRST COMMERCIAL SALE IS ACHIEVED PRIOR TO YEAR END, GENMAB EXPECTS TO UPDATE ITS FINANCIAL GUIDANCE AT THAT TIME​

* FIRST COMMERCIAL SALE COULD TAKE PLACE IN EITHER LATE 2017 OR EARLY 2018, GENMAB IS NOT UPDATING ITS FINANCIAL GUIDANCE FOR 2017​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below